The successful of transplantation is determined by the shared human leukocyte antigens(HLAs) and ABO blood group antigens between donor and recipient. In recent years, killer cell receptor [i.e., killer cell immunoglo...The successful of transplantation is determined by the shared human leukocyte antigens(HLAs) and ABO blood group antigens between donor and recipient. In recent years, killer cell receptor [i.e., killer cell immunoglobulinlike receptor(KIR)] and major histocompatibility complex(MHC) class I chain-related gene molecule(i.e., MICA) were also reported as important determinants of transplant compatibility. At present, several different genotyping techniques(e.g., sequence specific primer and sequence based typing) can be used to characterize blood group, HLA, MICA and KIR and loci. These molecular techniques have several advantages because they do not depend on the availability of anti-sera, cellular expression and have greater specificity and accuracy compared with the antibody-antigen based typing. Nonetheless, these molecular techniques have limited capability to capture increasing number of markers which have been demonstrated to determine donor and recipient compatibility. It is now possible to genotype multiple markers and to the extent of a complete sequencing of the human genome using next generation sequencer(NGS). This high throughput genotyping platform has been tested for HLA, and it is expected that NGS will be used to simultaneously genotype a large number of clinically relevant transplantation genes in near future. This is not far from reality due to the bioinformatics support given by the immunogenetics community and the rigorous improvement in NGS methodology. In addition, new developments in immune tolerance based therapy, donor recruitment strategies and bioengineering are expected to provide significant advances in the field of transplantation medicine.展开更多
AIM: To help clarifying the possibility of connective-tissue diseases in men with penile or testicular prostheses. METHODS: Eight patients underwent inflatable penile prostheses and 15, testicular prostheses consented...AIM: To help clarifying the possibility of connective-tissue diseases in men with penile or testicular prostheses. METHODS: Eight patients underwent inflatable penile prostheses and 15, testicular prostheses consented to the study. Their medical records were reviewed and a follow-up interview and physical and serological examinations were performed. RESULTS: In patients with penile prostheses, there was no abnormal antinuclear antibody (ANA) or IgM elevation. The serum levels of the rheumatoid factor (RF), C4, IgA and IgG were abnormal in one patient, and the levels of erythrocyte sedimentation rate (ESR) and C3, abnormal in two. Four had elevated IgE. In patients with testicular prostheses, there was no abnormal RF, ANA or IgM. The serum levels of ESR and IgA were abnormal in two, and three had abnormal C4, ten abnormal C3, and eleven decreased IgG. All had increased IgE. Men with penile prostheses had higher serum levels of IgG and IgM than those with testicular prostheses (P=0.001, P=0.016, respectively). The rates of abnormal values of IgE and IgG were higher in men with testicular prostheses than in men with penile prostheses (P=0.008, P=0.009, respectively). Physical examination was normal in all patients and nobody had documented symptoms pertinent to connective-tissue diseases. CONCLUSION: Our findings suggest that the risk of connective-tissue diseases is not higher in patients wearing prostheses as the ANA is negative and there is no apparent manifestation suggestive of connective-tissue diseases.展开更多
目的建立人免疫球蛋白产品中甲肝抗体效价ELISA检测方法,并对该方法进行验证及初步应用,以期满足《中国药典》三部(2015版)对人免疫球蛋白产品中甲肝抗体效价的质量控制检测要求。方法将人免疫球蛋白甲肝抗体国际标准品(97/646)稀释后,...目的建立人免疫球蛋白产品中甲肝抗体效价ELISA检测方法,并对该方法进行验证及初步应用,以期满足《中国药典》三部(2015版)对人免疫球蛋白产品中甲肝抗体效价的质量控制检测要求。方法将人免疫球蛋白甲肝抗体国际标准品(97/646)稀释后,采用建立的ELISA法检测甲肝抗体效价,分别验证方法的线性、准确性和精密度,试验均重复3次。应用建立的方法检测我国3家企业共13批人免疫球蛋白产品中的甲肝抗体效价。结果甲肝抗体效价在10~50 m IU/ml浓度范围内线性良好,相关系数为0.994 8;用建立的方法检测浓度为15、25、35 m IU/ml人免疫球蛋白甲肝抗体国际标准品的回收率在86.9%~104.4%之间,3次测定结果的相对标准偏差(relative standard deviation,RSD)均小于10%。用建立的方法检测我国3家企业共13批人免疫球蛋白产品中的甲肝抗体效价,结果均低于《中国药典》三部(2015版)对甲肝抗体效价不低于100 IU/ml的新增要求。结论建立的ELISA方法快速、准确,可用于检测我国人免疫球蛋白产品的甲肝抗体效价。展开更多
文摘The successful of transplantation is determined by the shared human leukocyte antigens(HLAs) and ABO blood group antigens between donor and recipient. In recent years, killer cell receptor [i.e., killer cell immunoglobulinlike receptor(KIR)] and major histocompatibility complex(MHC) class I chain-related gene molecule(i.e., MICA) were also reported as important determinants of transplant compatibility. At present, several different genotyping techniques(e.g., sequence specific primer and sequence based typing) can be used to characterize blood group, HLA, MICA and KIR and loci. These molecular techniques have several advantages because they do not depend on the availability of anti-sera, cellular expression and have greater specificity and accuracy compared with the antibody-antigen based typing. Nonetheless, these molecular techniques have limited capability to capture increasing number of markers which have been demonstrated to determine donor and recipient compatibility. It is now possible to genotype multiple markers and to the extent of a complete sequencing of the human genome using next generation sequencer(NGS). This high throughput genotyping platform has been tested for HLA, and it is expected that NGS will be used to simultaneously genotype a large number of clinically relevant transplantation genes in near future. This is not far from reality due to the bioinformatics support given by the immunogenetics community and the rigorous improvement in NGS methodology. In addition, new developments in immune tolerance based therapy, donor recruitment strategies and bioengineering are expected to provide significant advances in the field of transplantation medicine.
文摘AIM: To help clarifying the possibility of connective-tissue diseases in men with penile or testicular prostheses. METHODS: Eight patients underwent inflatable penile prostheses and 15, testicular prostheses consented to the study. Their medical records were reviewed and a follow-up interview and physical and serological examinations were performed. RESULTS: In patients with penile prostheses, there was no abnormal antinuclear antibody (ANA) or IgM elevation. The serum levels of the rheumatoid factor (RF), C4, IgA and IgG were abnormal in one patient, and the levels of erythrocyte sedimentation rate (ESR) and C3, abnormal in two. Four had elevated IgE. In patients with testicular prostheses, there was no abnormal RF, ANA or IgM. The serum levels of ESR and IgA were abnormal in two, and three had abnormal C4, ten abnormal C3, and eleven decreased IgG. All had increased IgE. Men with penile prostheses had higher serum levels of IgG and IgM than those with testicular prostheses (P=0.001, P=0.016, respectively). The rates of abnormal values of IgE and IgG were higher in men with testicular prostheses than in men with penile prostheses (P=0.008, P=0.009, respectively). Physical examination was normal in all patients and nobody had documented symptoms pertinent to connective-tissue diseases. CONCLUSION: Our findings suggest that the risk of connective-tissue diseases is not higher in patients wearing prostheses as the ANA is negative and there is no apparent manifestation suggestive of connective-tissue diseases.
文摘目的建立人免疫球蛋白产品中甲肝抗体效价ELISA检测方法,并对该方法进行验证及初步应用,以期满足《中国药典》三部(2015版)对人免疫球蛋白产品中甲肝抗体效价的质量控制检测要求。方法将人免疫球蛋白甲肝抗体国际标准品(97/646)稀释后,采用建立的ELISA法检测甲肝抗体效价,分别验证方法的线性、准确性和精密度,试验均重复3次。应用建立的方法检测我国3家企业共13批人免疫球蛋白产品中的甲肝抗体效价。结果甲肝抗体效价在10~50 m IU/ml浓度范围内线性良好,相关系数为0.994 8;用建立的方法检测浓度为15、25、35 m IU/ml人免疫球蛋白甲肝抗体国际标准品的回收率在86.9%~104.4%之间,3次测定结果的相对标准偏差(relative standard deviation,RSD)均小于10%。用建立的方法检测我国3家企业共13批人免疫球蛋白产品中的甲肝抗体效价,结果均低于《中国药典》三部(2015版)对甲肝抗体效价不低于100 IU/ml的新增要求。结论建立的ELISA方法快速、准确,可用于检测我国人免疫球蛋白产品的甲肝抗体效价。
